What Is MM120 (LSD D-Tartrate)?
MM120 (LSD D-Tartrate) is an investigational psychoactive and psychedelic drug currently being studied in clinical trials for various mental health conditions. It is designed to mediate its effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A). This mechanism of action can lead to intensified thoughts, emotions, and sensory perception. At sufficiently high dosages, MM120 may manifest primarily visual, as well as auditory, hallucinations.
MM120 is being investigated for its potential therapeutic uses in conditions such as Generalized Anxiety Disorder, Attention Deficit Disorder, and Major Depressive Disorder. Clinical trials for MM120 began on January 21, 2022, with the latest trial starting on April 24, 2025. A total of 5 clinical trials have been initiated for this drug, enrolling approximately 850 participants. Definium Therapeutics US, Inc. is the sponsor for all current studies involving MM120.
Uses and Conditions Under Study
MM120 (LSD D-Tartrate) is currently under investigation in clinical trials for several mental health conditions. Its psychoactive properties and interaction with serotonin receptors suggest potential therapeutic benefits for disorders affecting mood, thought, and attention.
One primary area of study for MM120 is anxiety disorders. This includes trials for Generalized Anxiety Disorder and Anxiety Generalized, which together account for 3 trials. Generalized Anxiety Disorder is characterized by persistent and excessive worry about various everyday issues. Given MM120's effects on perception and emotions, researchers are exploring its ability to modulate anxiety responses.
Another area of focus is attention disorders, specifically ADHD (Attention Deficit Hyperactivity Disorder) and Attention Deficit Disorder. These conditions involve difficulties with focus, impulsivity, and hyperactivity. MM120's influence on sensory perception and cognitive processes is being studied in 2 trials to understand its potential role in improving attention and executive function.
Finally, MM120 is also being investigated in 1 trial for Major Depressive Disorder. This condition involves persistent feelings of sadness, loss of interest, and other emotional and physical problems. The psychedelic effects of MM120, which can lead to shifts in perspective and emotional processing, are being explored as a potential treatment approach for depression.
Dosing
Clinical trials for MM120 (LSD D-Tartrate) have explored various strengths of the investigational drug. The specific dosage form, such as a tablet or oral solution, is not detailed in the available trial information. However, different microgram (µg) doses have been administered to participants across the studies to assess safety, tolerability, and potential efficacy.
The strengths of MM120 that have been studied include:
- 25 µg
- 50 µg
- 100 µg
- 200 µg
These doses are being evaluated in participants enrolled in trials for conditions such as Generalized Anxiety Disorder, ADHD, and Major Depressive Disorder. The specific frequency or method of administration (e.g., once daily, as a single dose) is determined by the protocol of each individual clinical trial. Information regarding standard adult doses or specific pediatric doses is not available as MM120 is still in the investigational phase, and optimal dosing regimens are still being established.
Side Effects
In clinical trials, patients taking MM120 (LSD D-Tartrate) experienced certain side effects more often than those taking a placebo. The most common side effect was illusion, reported by 47.8% of patients on MM120, compared to 4.6% on placebo (across 2 trials, n=186). Nausea was also common, affecting 31.7% of MM120 patients versus 6.2% on placebo (across 2 trials, n=186).
Other frequently reported side effects with MM120 included:
- Visual hallucination: 18.9% of patients on MM120 experienced this, compared to 2.6% on placebo (from 1 trial, n=159).
- Euphoric mood: Reported by 13.4% of MM120 patients versus 1.5% on placebo (across 2 trials, n=186).
- Mydriasis (dilated pupils): Occurred in 12.6% of MM120 patients versus 2.6% on placebo (from 1 trial, n=159).
- Anxiety: Experienced by 11.9% of MM120 patients compared to 5.1% on placebo (from 1 trial, n
Currently Recruiting Trials
Currently, two important Phase 3 clinical trials are actively recruiting participants to evaluate MM120 (LSD D-Tartrate) for Generalized Anxiety Disorder. These studies, sponsored by Definium Therapeutics US, Inc., aim to understand how MM120 might help people living with this condition.
One such trial, known as Panorama (NCT06809595), is a Phase 3, double-blind, placebo-controlled study with an open-label extension. It is designed to evaluate MM120 compared to a placebo in individuals with Generalized Anxiety Disorder. Participants in this study will receive either 50µg or 100µg of MM120 (LSD D-Tartrate) or a placebo. The trial is seeking to enroll approximately 250 participants.
Similarly, the Voyage study (NCT06741228) is also a Phase 3, double-blind, placebo-controlled study with an open-label extension, focusing on Generalized Anxiety Disorder. This trial is evaluating a 100µg dose of MM120 (LSD D-Tartrate) against a placebo. The Voyage study aims to enroll around 200 participants.
Both trials are looking for individuals between the ages of 18 and 74 who have Generalized Anxiety Disorder. Healthy volunteers and children are not eligible to participate.
Where to Participate
If you are interested in participating in a clinical trial for MM120, studies are currently recruiting across a wide geographic area. There are 46 sites located in 43 cities across 21 states.
Top locations include:
- Austin, Texas
- New York, New York
- Atlanta, Georgia
- Boston, Massachusetts
- Los Angeles, California
- Santa Monica, California
- Torrance, California
- Denver, Colorado
- Bradenton, Florida
- Jacksonville, Florida
To be eligible for these studies, participants must be between 18 and 74 years old. The trials are open to all genders. It is important to note that these studies are designed for individuals with Generalized Anxiety Disorder, so healthy volunteers and children are not eligible to participate.
Development Timeline
The journey of MM120 (LSD D-Tartrate) in clinical development began on January 21, 2022, with its first clinical trial. Since then, Definium Therapeutics US, Inc. has been the sole sponsor, driving all development efforts for this compound.
Initially, MM120 was explored for conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. Over time, the research expanded to investigate its potential in a broader range of neurological and psychiatric conditions. The development pipeline now includes studies for Generalized Anxiety Disorder, Attention Deficit Disorder, and Major Depressive Disorder, reflecting a strategic expansion of its therapeutic focus.
To date, a total of 5 clinical trials have been initiated for MM120, enrolling approximately 850 participants. These studies have progressed through various stages, with two trials reaching Phase 2 and three trials currently in Phase 3, including the ongoing studies for Generalized Anxiety Disorder. The latest trial is projected to conclude by April 24, 2025, marking continued progress in understanding MM120's potential.